Anthrax is an acute infectious disease caused by the spore-forming bacterium Bacillus anthracis. Anthrax most commonly occurs in wild and domestic lower vertebrates (cattle, sheep, goats, camels, antelopes, and other herbivores), but it can also occur in humans when they are exposed to infected animals or tissue from infected animals.
Anthrax is most common in agricultural regions where it occurs in animals. These include South and Central America, Southern and Eastern Europe, Asia, Africa, the Caribbean, and the Middle East. When anthrax affects humans, it is usually due to an occupational exposure to infected animals or their products. Workers who are exposed to dead animals and animal products from other countries where anthrax is more common may become infected with B. anthracis (industrial anthrax). Anthrax outbreaks occur in the United States on an annual basis in livestock and wild game animals such as deer.
Anthrax infection can occur in three forms: cutaneous (skin), inhalation, and gastrointestinal. B. anthracis spores can live in the soil for many years, and humans can become infected with anthrax by handling products from infected animals or by inhaling anthrax spores from contaminated animal products. Anthrax can also be spread by eating undercooked meat from infected animals. It is rare to find infected animals in the United States.
Bacteria are omnipresent - in the water, the air and the soil, as well as in plants, animals and even people. We tend to think of bacteria as pathogenic, causing disease. We associate them with intestinal upsets and throat infections, pneumonia and blood poisoning.
The latest episode in the American Chemical Society's (ACS') award-winning Global Challenges/Chemistry Solutions podcast series describes a simple, inexpensive dip-and-dry treatment can convert ordinary silk into a fabric that kills disease-causing bacteria - even the armor-coated spores of microbes like anthrax - in minutes.
A special feature in this week's issue of the journal Science highlights protein array technology, touching on research conducted by Joshua LaBaer, director of the Biodesign Institute's Virginia G. Piper Center for Personalized Diagnostics.
Today's headlines include a report that congressional conservatives are fighting amongst themselves over health law strategies.
Emergent BioSolutions Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved its supplemental Biologics License Application (sBLA) to change the administration schedule of BioThrax (Anthrax Vaccine Adsorbed) to a three-dose primary series of intramuscular injections at 0, 1, and 6 months.
Soligenix, Inc., a development stage biopharmaceutical company, announced today its financial results for the quarter ending March 31, 2012.
Aradigm Corporation today announced financial results for the first quarter and three months ended March 31, 2012.
iBio, Inc. today announced issuance of a US patent covering compositions of matter and methods of use of modified lichenase B polypeptides comprising the Company's iBioModulator platform.
Neighbors were already concerned about the growing number of group homes for the elderly and recovering addicts in the area, many of them for profit. A Times analysis found 24 licensed facilities offering residential care for the elderly within a mile of the proposed project and three more waiting for state approval. It is one of several such clusters that have emerged in Los Angeles County -- including parts of the San Fernando Valley and South Bay -- where families can afford fees that run into thousands of dollars per month. Large swaths of the county's less affluent areas have no such facilities.
D.C. Council member David A. Catania has found an additional $20 million in the budget to continue offering free health insurance to 19,000 undocumented immigrants, reversing a proposal by Mayor Vincent C. Gray (D) that could have restricted them from receiving emergency care. Catania (I-At Large) … has made full funding of the Alliance Insurance program a chief priority as the council prepares for final budget deliberations.
Soldiers in war zones and farmers tending their fields can have in common chronic exposure to chemicals that impact their nerves.
PaxVax Corporation, developer of innovative and socially responsible oral vaccines against infectious diseases, announced that the U.S. Food and Drug Administration (FDA) has accepted its investigational new drug (IND) application for its single-dose oral cholera vaccine, clearing the way to begin clinical trials. The company intends to begin Phase 3 trials later this year.
Aradigm Corporation today announced that the Company's Investigational New Drug Application (IND) to conduct a pivotal Phase 3 clinical trial of Pulmaquin (dual release ciprofloxacin for inhalation) in non-cystic fibrosis bronchiectasis (BE) has been cleared by the U.S. Food and Drug Administration.
New York hookers spreading HIV. Killer mosquitos. An anthrax-toting terrorist. An urban-scape rife with the sick and poor. These are just some of the challenges tackled by Farzad Mostashari, a Yale-educated physician, epidemiologist and self-confessed computer nerd. His current mission: moving doctors from the Age of Gutenberg into the 21st century. For starters, he'd like them to use e-mail at the office.
Emergent BioSolutions Inc. announced today its financial results for the fourth quarter and full year ended December 31, 2011.
PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats, today reported its financial and operational results for the year ended December 31, 2011.
More than 70 years after the first sulfa drugs helped to revolutionize medical care and save millions of lives, St. Jude Children's Research Hospital scientists have determined at an atomic level the mechanism these medications use to kill bacteria. The discovery provides the basis for a new generation of antibiotics that would likely be harder for bacteria to resist and cause fewer side effects.
Sandia's decontamination foam, developed more than a decade ago and used to decontaminate federal office buildings and mailrooms during the 2001 anthrax attacks, is now being used to decontaminate illegal methamphetamine labs.
Soligenix, Inc., a development stage biopharmaceutical company, announced preliminary results today from a Phase 1/2 clinical trial evaluating SGX201, a time-release formulation of oral beclomethasone 17,21-dipropionate (oral BDP), for the prevention of acute radiation enteritis.
Soligenix, Inc., a development stage biopharmaceutical company, announced today results from preclinical studies of its proprietary vaccine thermostabilization technology indicating that Soligenix is able to produce stable vaccine formulations using adjuvants, protein immunogens, and other components that ordinarily would not withstand long temperature variations exceeding customary refrigerated storage conditions.